KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826.

Sharon M Castellino, Hongli Li, Alex F Herrera, Michael LeBlanc, Susan K Parsons, Joseph M Unger, Angela Punnett, David Hodgson, Frank G Keller, Richard A Drachtman, Adam Lamble, Christopher J Forlenza, Andrew Doan, Sarah C Rutherford, Andrew M Evens, Richard F Little, Malcolm A Smith, Bradford S Hoppe, Joo Y Song, Sonali M Smith, Jonathan W Friedberg, Kara M Kelly

J Clin Oncol 44(6) 449-454

PMID41512237
PMCIDPMC13192332
DOI10.1200/JCO-25-00203
发表日期2026-01-09
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

We present a subset analysis on the adolescent cohort of the S1826 randomized phase three trial, comparing nivolumab, doxorubicin, vinblastine, dacarbazine (N-AVD) to brentuximab vedotin-AVD (BV-AVD) in newly diagnosed advanced-stage (AS, stages III and IV) classic Hodgkin lymphoma (cHL). Among 994 patients enrolled, 24% (n = 240) were age 12-17 years. The 3-year progression-free survival (PFS) was significantly higher in the N-AVD group (93% [95% CI, 87 to 96]) compared with the BV-AVD group (82% [95% CI, 73 to 88]; hazard ratio, 0.37 [95% CI, 0.17 to 0.80]). One N-AVD and two BV-AVD patients received protocol-specified residual site radiotherapy (RT). Rates of febrile neutropenia and sepsis were low in both groups. Severe immune-related adverse events were infrequent, although thyroid dysfunction was seen in 7% with N-AVD. Sensory neuropathy (grade ≥2) was more frequent with BV-AVD (14% v 7%) by clinician report. Although premature discontinuation of therapy was reported in 12 N-AVD patients and four BV-AVD patients, no PFS events were noted in the N-AVD group. Patient-reported outcomes indicated less toxicity with N-AVD. N-AVD demonstrated high 3-year PFS in adolescents with AS cHL, with minimal RT use. S1826 exemplifies the benefits of harmonized clinical trial protocols, resulting in timely access to novel agents for adolescents.

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

Figure 1

Figure 1. a) 3-year Progression-Free survival (PFS) in adolescent patients with advanced stage cHL by study arm b) 3-year Progression-Free survival (PFS) in adolescent patients with Stage III cHL by study arm c) 3-year Progression-Free survival (PFS) in adolescent patients with Stage IV cHL by study arm d) 3-year Event-Free Survival by study arm, where events on N-AVD were due to non-protocol chemotherapy prior to progression (n=4); non protocol RT prior to progression (n=1) or progression of disease (n=9). With BV-AVD events were due to non-protocol chemotherapy prior to progression (n=1); non-protocol RT prior to progression (n=1) and progression of disease (n=22) and death (n=1). Note: the 95% CI for the hazard ratio (HR) is two-sided.

BV-AVD_vs_N-AVD_Progression-Free_Survival

Progression-Free Survival

Figure 1 · Panel BV-AVD_vs_N-AVD_Progression-Free_Survival

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel BV-AVD_vs_N-AVD_Progression-Free_Survival 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 1:off origin start曲线 1:extreme upward reversal曲线 2:extreme upward reversal
查看结果
Patients_at_Risk_Table

KM endpoint

Figure 1 · Panel Patients_at_Risk_Table

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel Patients_at_Risk_Table 是同一 Figure 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线缺失:预期 2 条,实际恢复 1 条曲线 1:short span
查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 2Figure 2. Tolerability of Nivolumab AVD vs. BV AVD as assessed by patient report on the Ped-PRO-CTCAE and by clinician grading on CTCAE. The odds ratios for physician-rated (gray) vs. patient-reported frequency (green) are presented by, severity (blue), and interference (red) for a given symptom. The odds ratios are provided on a log scale, along with the 95% confidence intervals. Anything above 1.0 (the line of equal odds) indicates more of a given symptom for the BV-AVD arm. Anything below 1.0 indicates more of a given symptom for the N-AVD arm. Evidence is delineated according to both “any evidence” (a Ped-PRO-CTCAE score >0) vs. “severe evidence” (Ped-PRO-CTCAE score >=2). Results were adjusted for the baseline Ped-PRO-CTCAE score, and compared using Fisher’s exact tests among patients with both baseline and follow-up scores. Patient-reported frequency for neuropathy and patient-reported severity for diarrhea were not included, as neither is available in the Peds PRO-CTCAE item library. No physician rates of severe abdominal pain or myalgia/arthralgia were reported.
非 KM Figure